NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

BioAge Labs, Inc. (BIOA) Stock Analysis

BioAge Labs, Inc. (BIOA) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

BIOA

$5.51

−$0.05 (−0.90%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BIOA with… →

BIOA Key Statistics

As of Oct 21, 2026
Trading
Open
$5.61
Previous Close
$5.56
Day's Range
5.43–5.70
52-Week Range
4.81–25.96
Volume
568.48K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.08
Valuation
Market Cap
$229.03M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
22.12
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.39
Financials (FY)
Revenue (FY)
$9.00M
Net Income (FY)
−$80.61M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
45.90M
1-Year Return
+3.96%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
931.70K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, BIOA closed at $5.51, +3.96% over 1 year.

BioAge Labs, Inc. (BIOA) has a market capitalization of $229.03M.

In fiscal 2025, BIOA reported revenue of $9.00M.

BIOA Stock Return by Calendar Year

BioAge Labs, Inc. (BIOA) return since Sep 2024: what $10,000 became

1 year
$10,000 $10,396
+3.96%
Since Sep 2024
$10,000 $3,009
−69.91%

If you had invested $10,000 in BioAge Labs, Inc. (BIOA) at the close on September 26, 2024, the earliest close on record here, it would have been worth $3,009 at the close on October 21, 2026: −69.91% in total, −44.06% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−58.35%
2025+128.50%
2024 (partial year)−68.38%

As of October 21, 2026.

BIOA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$9.00M−$80.61M−896.1%
2024$0.00−$71.11M—
2023$0.00−$63.85M—
2022$0.00−$39.72M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$9.00M—−$92.78M−$80.61M−896.1%
2024$0.00—−$78.19M−$71.11M—
2023$0.00—−$48.40M−$63.85M—
2022$0.00—−$39.97M−$39.72M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

BIOA Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 97 stocks
MetricBIOADrug Manufacturers - Specialty & Generic medianvs median
P/S ratio22.122.1010.5x the median

Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 16 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

BioAge Labs, Inc. (BIOA) is capitalised at $229.03M on the latest close. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. The company reports 60 employees.

BIOA last closed at $5.51 on October 21, 2026. That is −$0.05 (−0.90%) against the previous close. Over the past 52 weeks the price has ranged from $4.81 to $25.96. The latest close sits 14.55% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $9.00M. The same year closed with a net loss of $80.61M. Earnings per share on a trailing basis come to −2.39.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $9.00M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 22.12 times revenue. On price-to-sales that is 10.5 times the Drug Manufacturers - Specialty & Generic median of 2.1. The medians here are taken across 97 Drug Manufacturers - Specialty & Generic companies that report the metric.

The trailing one-year total return is +3.96%. The stored price history starts on September 26, 2024, and the total return since then is −69.91%. Beta against the wider market is reported at 1.08. Annualized volatility over the trailing 2 years is 105.3%.

Growth & Income

The record shows no dividend for BIOA.

The record holds one complete calendar year, 2025, which returned +128.50%. So far in 2026 the total return is −58.35%.

Peer Comparison

BioAge Labs, Inc. (BIOA) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
BioAge Labs, Inc. BIOA $229.03M —
Takeda Pharmaceutical Company Limited TAK $63.67B —
Teva Pharmaceutical Industries Limited TEVA $47.37B 67.7
Haleon plc HLN $44.06B 20.5

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.3x. BioAge Labs, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

 TEVA

Teva Pharmaceutical Industries Limited

$47.37B

 HLN

Haleon plc

$44.06B

 ZTS

Zoetis Inc.

$32.90B

 UTHR

United Therapeutics Corporation

$24.17B

 VTRS

Viatris Inc.

$21.19B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About BioAge Labs, Inc.

BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Visit website →